ABSTRACT #7508
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma...
ABSTRACT 8504
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response...
ABSTRACT LBA1008
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal...
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
Study findings were published in the May 29 online issue of the New England Journal of Medicine. Lead researchers included Nitin Jain, M.D., associate professor...
The University of Texas MD Anderson Cancer Center applauds the Texas Legislature today for passing Senate Bill 21, which raises the minimum...
The University of Texas MD Anderson Cancer Center today named David Jaffray, Ph.D., as its first-ever chief technology and digital officer...
Despite a Saturday morning storm that wreaked havoc on plans for this year’s Polo on the Prairie, May 18 at the Musselman Brothers’ Lazy 3...
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder...
The University of Texas MD Anderson Cancer Center applauds the 86th Texas Legislature today for voting to approve a constitutional amendment...
The University of Texas MD Anderson Cancer Center has received full accreditation by the American Association for Physician Leadership...
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered...
The University of Texas MD Anderson Cancer Center has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each...
A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer...